

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540

BALTIMORE

INNER HARBOR CENTER
400 EAST PRATT STREET, SUITE 800
BALTIMORE, MARYLAND 21202
(410) 659-7570

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOLOFF
WILLIAM C. ALLISON
MICHAEL O. LEE
EVELYN H. MCCONATHY
ERIC K. STEFFE
ANDREA G. REISTER
DANIEL N. YANNUZZI
CONO A. CARRANO
G. KEVIN TOWNSEND*
JOHN M. COVERT*
ANNE BROWN
MICHELE A. VAN PATTEN*
LINDA E. ALCORN
RAZ E. FLESHNER
PAUL A. BERNKOPF*
ROBERT C. MILLONIG

JAMES L. LEWIS*
OF COUNSEL

*BAR OTHER THAN D.C.

DONALD J. FEATHERSTONE
STEVEN R. LUDWIG
LAWRENCE B. BUGAISKY
KAREN R. MARKOWICZ
DREW GRANSTON
MICHAEL V. MESSINGER
DAVID C. ISAACSON
MEGAN D. DORTENZO
THOMAS M. DUNHAM

REGISTERED
PATENT AGENTS

WRITER'S DIRECT NUMBER:

December 8, 1995

18C
12-7-95
RECEIVED

DEC 14 1995

GROUP 1800

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 08/249,671; Filed: May 26, 1994
For: **Process for Preparing and Purifying Alpha-Interferon**
Inventors: Hauptmann *et al.*
Our Ref: 0652.1350000/RWE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Form PTO-1083 (in duplicate);
2. Amendment and Response Under 37 C.F.R. §§ 1.111 and 1.115; Amendment to Sequence Listing Under 37 C.F.R. § 1.825;
3. Paper and computer readable copy of Sequence Listing;
4. Copy of standard genetics text *Genes and Genomes* (Singer *et al.*, University Science Books, pp. 625-626, 1991);
5. Copy of J. E.F. Reynolds, ed., *Martindale*, The Pharmaceutical Press, London, p. 1270 (28th ed., 1982);

Assistant Commissioner for Patents

December 8, 1995

Page 2

6. Copy of Pestka, S., *et al.*, *Ann. Rev. Biochem.* 56: 730, 1987;
7. Certified copies of 35 U.S.C. § 119 priority applications, German application P 43 17 459.0, and German application P 43 29 756.0;
8. Copy of the Information Disclosure Statement, Form PTO-1449 (7 pages), and cited non-patent documents (AR1, AS1, AT1, AR2, AS2, AT2, AR3, AS3, AT3, AR4, AS4, AT4, AR5, AS5, AT5, AR6, AS6, AT6, AR7, AS7, and AT7) originally filed on November 15, 1994 (Paper No. 7); and
9. A return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE/LLK/ttp

p:\users\tpittman\0652\652135.CVR



378-0294

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HAUPTMANN et al.

Appl. No.: 08/249,671

Filed: May 26, 1994

For: **Process for Preparing and Purifying
Alpha-Interferon**

Art Unit: 1812

Examiner: Fitzgerald, D

Atty Docket: 0652.1350000/RWE

RECEIVED

DEC 14 1995

GROUP 1800

12/B
1593
2/29/96

**Amendment and Response Under 37 C.F.R. §§ 1.111 & 1.115;
Amendment to Sequence Listing Under 37 C.F.R. § 1.825**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Responsive to the Office Action dated September 8, 1995 (Paper No. 9), Applicants respectfully request reconsideration and reexamination of the above-captioned patent application in view of the following Amendment and Remarks.

In the Specification:

At p. 4, l. 20, before "exchange" please insert --cation--.

At p. 4, l. 21, before "exchange" please insert --anion--.

At p. 4, l. 27, please delete "9-10" and insert therefor --8-9--.

At p. 5, l. 5, please delete "11-12" and insert therefor --10-11--.

At p. 5, l. 12, please delete "phenylsepharose" and insert therefor --phenyl Sepharose™--.

At p. 5, l. 18, please delete "sepharose" and insert therefor --Sepharose Fast Flow™--.

B